164 related articles for article (PubMed ID: 21252251)
1. Decreased cerebrospinal fluid/plasma ratio of the novel satiety molecule, nesfatin-1/NUCB-2, in obese humans: evidence of nesfatin-1/NUCB-2 resistance and implications for obesity treatment.
Tan BK; Hallschmid M; Kern W; Lehnert H; Randeva HS
J Clin Endocrinol Metab; 2011 Apr; 96(4):E669-73. PubMed ID: 21252251
[TBL] [Abstract][Full Text] [Related]
2. The relation of serum nesfatin-1 level with metabolic and clinical parameters in obese and healthy children.
Abaci A; Catli G; Anik A; Kume T; Bober E
Pediatr Diabetes; 2013 May; 14(3):189-95. PubMed ID: 23346951
[TBL] [Abstract][Full Text] [Related]
3. NUCB2/nesfatin-1 is associated with elevated scores of anxiety in female obese patients.
Hofmann T; Stengel A; Ahnis A; Buße P; Elbelt U; Klapp BF
Psychoneuroendocrinology; 2013 Nov; 38(11):2502-10. PubMed ID: 23796625
[TBL] [Abstract][Full Text] [Related]
4. Plasma nesfatin-1 level in obese patients after acupuncture: a randomised controlled trial.
Guo Y; Xing M; Sun W; Yuan X; Dai H; Ding H
Acupunct Med; 2014 Aug; 32(4):313-7. PubMed ID: 24813558
[TBL] [Abstract][Full Text] [Related]
5. Nesfatin-1 in childhood and adolescent obesity and its association with food intake, body composition and insulin resistance.
Anwar GM; Yamamah G; Ibrahim A; El-Lebedy D; Farid TM; Mahmoud R
Regul Pept; 2014 Jan; 188():21-4. PubMed ID: 24333832
[TBL] [Abstract][Full Text] [Related]
6. Fibroblast growth factor 21 (FGF21) in human cerebrospinal fluid: relationship with plasma FGF21 and body adiposity.
Tan BK; Hallschmid M; Adya R; Kern W; Lehnert H; Randeva HS
Diabetes; 2011 Nov; 60(11):2758-62. PubMed ID: 21926274
[TBL] [Abstract][Full Text] [Related]
7. Increased plasma levels of nesfatin-1 in patients with newly diagnosed type 2 diabetes mellitus.
Zhang Z; Li L; Yang M; Liu H; Boden G; Yang G
Exp Clin Endocrinol Diabetes; 2012 Feb; 120(2):91-5. PubMed ID: 22020667
[TBL] [Abstract][Full Text] [Related]
8. The newly identified anorexigenic adipokine nesfatin-1 in hemodialysis patients: Are there associations with food intake, body composition and inflammation?
Saldanha JF; Carrero JJ; Lobo JC; Stockler-Pinto MB; Leal VO; Calixto A; Geloneze B; Mafra D
Regul Pept; 2012 Jan; 173(1-3):82-5. PubMed ID: 22036920
[TBL] [Abstract][Full Text] [Related]
9. Association of nesfatin-1 level with body composition, dietary intake and resting metabolic rate in obese and morbid obese subjects.
Mirzaei K; Hossein-nezhad A; Keshavarz SA; Koohdani F; Eshraghian MR; Saboor-Yaraghi AA; Hosseini S; Chamari M; Zareei M; Djalali M
Diabetes Metab Syndr; 2015; 9(4):292-8. PubMed ID: 25470645
[TBL] [Abstract][Full Text] [Related]
10. Fasting and postprandial levels of a novel anorexigenic peptide nesfatin in childhood obesity.
Anık A; Çatlı G; Abacı A; Küme T; Bober E
J Pediatr Endocrinol Metab; 2014 Jul; 27(7-8):623-8. PubMed ID: 24825087
[TBL] [Abstract][Full Text] [Related]
11. Sex-specific regulation of NUCB2/nesfatin-1: Differential implication in anxiety in obese men and women.
Hofmann T; Elbelt U; Ahnis A; Rose M; Klapp BF; Stengel A
Psychoneuroendocrinology; 2015 Oct; 60():130-7. PubMed ID: 26143537
[TBL] [Abstract][Full Text] [Related]
12. Effects of upper-body resistance exercise training on serum nesfatin-1 level, insulin resistance, and body composition in obese paraplegic men.
Mogharnasi M; TaheriChadorneshin H; Papoli-Baravati SA; Teymuri A
Disabil Health J; 2019 Jan; 12(1):29-34. PubMed ID: 30061073
[TBL] [Abstract][Full Text] [Related]
13. Alterations of circulating NUCB2/nesfatin-1 during short term therapeutic improvement of anxiety in obese inpatients.
Hofmann T; Weibert E; Ahnis A; Obbarius A; Elbelt U; Rose M; Klapp BF; Stengel A
Psychoneuroendocrinology; 2017 May; 79():107-115. PubMed ID: 28273586
[TBL] [Abstract][Full Text] [Related]
14. Association of nesfatin-1 and fat mass in cystic fibrosis.
Cohen RI; Ginsberg N; Tsang D; Wann LC; Ye X; Liu SF
Respiration; 2013; 86(4):312-7. PubMed ID: 23306670
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal fluid ghrelin is negatively associated with body mass index.
Tritos NA; Kokkinos A; Lampadariou E; Alexiou E; Katsilambros N; Maratos-Flier E
J Clin Endocrinol Metab; 2003 Jun; 88(6):2943-6. PubMed ID: 12788909
[TBL] [Abstract][Full Text] [Related]
16. [Analysis of serum levels of nesfatin-1 in children and adolescents with autoimmune thyroid diseases].
Sawicka B; Bossowski A
Pediatr Endocrinol Diabetes Metab; 2013; 19(1):5-10. PubMed ID: 23739643
[TBL] [Abstract][Full Text] [Related]
17. Relationship of plasma leptin to plasma insulin and adiposity in normal weight and overweight women: effects of dietary fat content and sustained weight loss.
Havel PJ; Kasim-Karakas S; Mueller W; Johnson PR; Gingerich RL; Stern JS
J Clin Endocrinol Metab; 1996 Dec; 81(12):4406-13. PubMed ID: 8954050
[TBL] [Abstract][Full Text] [Related]
18. Plasma nesfatin-1 concentrations in restricting-type anorexia nervosa.
Ogiso K; Asakawa A; Amitani H; Nakahara T; Ushikai M; Haruta I; Koyama K; Amitani M; Harada T; Yasuhara D; Inui A
Peptides; 2011 Jan; 32(1):150-3. PubMed ID: 20937336
[TBL] [Abstract][Full Text] [Related]
19. A novel appetite peptide, nesfatin-1 in patients with non-alcoholic fatty liver disease.
Başar O; Akbal E; Köklü S; Koçak E; Tuna Y; Ekiz F; Gültuna S; Yιlmaz FM; Aydoğan T
Scand J Clin Lab Invest; 2012 Oct; 72(6):479-83. PubMed ID: 22950627
[TBL] [Abstract][Full Text] [Related]
20. Identification of nesfatin-1 in human and murine adipose tissue: a novel depot-specific adipokine with increased levels in obesity.
Ramanjaneya M; Chen J; Brown JE; Tripathi G; Hallschmid M; Patel S; Kern W; Hillhouse EW; Lehnert H; Tan BK; Randeva HS
Endocrinology; 2010 Jul; 151(7):3169-80. PubMed ID: 20427481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
